CytRx

CytRx is a biopharmaceutical company based in Los Angeles, California. The company specializes in the discovery, development, and commercialization of novel, chemically-enhanced drugs and therapies. These are primarily used in the treatment of cancer and neurodegenerative disorders.

History[edit | edit source]

CytRx was founded in 1985 by Dr. Jack Barber. The company initially focused on the development of superconducting materials and surface acoustic wave (SAW) devices. However, in the early 2000s, CytRx shifted its focus to the development of biopharmaceutical drugs.

Research and Development[edit | edit source]

CytRx's research and development efforts are primarily focused on the development of small molecule drugs. These drugs are designed to treat diseases by modulating the activity of key proteins involved in the disease process. The company's lead drug candidate, aldoxorubicin, is a chemically-enhanced version of the widely used chemotherapeutic agent doxorubicin. Aldoxorubicin is currently in Phase 3 clinical trials for the treatment of soft tissue sarcoma.

Partnerships[edit | edit source]

CytRx has formed strategic partnerships with several other biopharmaceutical companies to further its drug development efforts. These partnerships have allowed CytRx to leverage the expertise and resources of its partners to accelerate the development of its drug candidates.

Financials[edit | edit source]

As a publicly traded company, CytRx's financial performance is closely watched by investors and analysts. The company's stock is traded on the NASDAQ stock exchange under the ticker symbol "CYTR".